Search clinical trials for: Anti-TIGIT antibody

Total 5253 results

Beijing 302 Hospital
Beijing GD Initiative Cell Therapy Technology Co., Ltd.; Chinese Academy of...

Not yet recruiting

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody

Hepatocellular Carcinoma
Anhui Provincial Hospital

Not yet recruiting

The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT

High Titers of Anti-HLA Antibody (MFI ≥5000)

China
Shanghai Zhongshan Hospital
Sun Yat-sen University; Eastern Hepatobiliary Surgery Hospital

Not yet recruiting

Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC

Hepatocellular Carcinoma

China
Byondis B.V.

Recruiting

Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

Relapsed / Refractory AML | Relapsed / Refractory MDS

Spain, Netherlands, Belgium
Changchun BCHT Biotechnology Co.
The First Affiliated Hospital of Yunnan University of Traditional Chinese... and other collaborators

Not yet recruiting

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection Combination Formulation

Clostridium Tetanus
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Not yet recruiting

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Sanofi

Not yet recruiting

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (SubQSA)

Plasma Cell Myeloma Refractory
Beijing 302 Hospital

Recruiting

The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients

Chronic Hepatitis B

China
Children's National Research Institute
The Hospital for Sick Children; Ann & Robert H Lurie Children's Hospital of... and other collaborators

Recruiting

Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell AntibodY (SUN-RAY)

Sickle Cell Disease

United States
The Affiliated Hospital of Qingdao University

Recruiting

Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer (PILOT)

Non-small-cell Lung Cancer (NSCLC)

China
OncoC4, Inc.

Not yet recruiting

Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

Advanced Solid Tumor

United States
Zhejiang Cancer Hospital

Recruiting

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Gastric Cancer | Colorectal Cancer | Pancreatic Adenocarcinoma | Biliary Tract Cancer | Gastroesophageal Junction Adenocarcinoma | Liver Cancer Stage IV

China
Essen Biotech

Not yet recruiting

Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) (BAH242)

Autoimmune Diseases | Systemic Lupus Erythematosus | Systemic Sclerosis | Lupus Nephritis | Microscopic Polyangiitis | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Sjogren's Syndrome | Idiopathic Inflammatory Myopathies | Granulomatous Polyangiitis

China
Thomas Martin, MD
Bristol-Myers Squibb; Janssen Research & Development, LLC

Not yet recruiting

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

Prostate Cancer

United States
The First Affiliated Hospital with Nanjing Medical...

Recruiting

A Clinical Study of Omalizumab in the Treatment of Allergic Asthma(ESSENCE) (ESSENCE)

Moderate to Severe Allergic Asthma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC

Head and Neck Cancer

China
BioNTech SE
DualityBio Inc.

Not yet recruiting

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Endometrial Cancer
National Cancer Institute (NCI)

Not yet recruiting

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Classic Follicular Lymphoma | Follicular Lymphoma With Unusual Cytological Features
University of Southern California
National Cancer Institute (NCI)

Not yet recruiting

Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8

United States
Hansoh BioMedical R&D Company

Not yet recruiting

HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors

Advanced Solid Tumors
Wang Xin

Not yet recruiting

Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT

GVHD

China
Henan Cancer Hospital

Not yet recruiting

PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer

Metastatic Colon Cancer
Fujian Cancer Hospital

Not yet recruiting

A Phase II Multicenter Clinical Study of Improved Short-course Radiotherapy Combined With CAPOX and PD-1 Monoclonal Antibody for Locally Advanced Mid-low Rectal Cancer

Mid-low Rectal Cancer
Novartis Pharmaceuticals

Recruiting

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) (REPLENISH-EXT)

Polymyalgia Rheumatica

Australia
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer

Advanced Breast Cancer | Metastatic Breast Cancer

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis

Dermatitis, Atopic
Sun Yat-sen University

Recruiting

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Recruiting

Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma | Bevacizumab | Anti-PD1/PDL1 Antibody

China
Emory University
National Cancer Institute (NCI)

Not yet recruiting

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
University of Rochester

Not yet recruiting

The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration

Age-Related Macular Degeneration | Retinitis Pigmentosa | Retinal Dystrophies | Alcohol Use Disorder | Stargardt Disease

United States
Bio-Thera Solutions

Recruiting

BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer

Endometrial Cancer

China
OHSU Knight Cancer Institute
Oregon Health and Science University; Incyte Corporation

Recruiting

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Not yet recruiting

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

B Acute Lymphoblastic Leukemia | Acute Leukemia of Ambiguous Lineage
RenJi Hospital
Guangdong Ruishun Biotech Co., Ltd

Recruiting

Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases

Systemic Lupus Erythematosus | Systemic Sclerosis | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Idiopathic Inflammatory Myopathies

China
Ruijin Hospital

Recruiting

Effect of Telitacicept on Antibody Titers in Primary APS Patients

Antiphospholipid Syndrome (APS)

China
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).

Allergic Rhinitis
Chen Xiaoping

Recruiting

Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma

HCC

China
National Cancer Institute (NCI)

Not yet recruiting

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm
Nanfang Hospital, Southern Medical University

Not yet recruiting

Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial

Gastric Cancer | Esophagogastric Junction Cancer

China
AstraZeneca

Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants

Healthy Participants Study

United States
Shanghai Henlius Biotech

Recruiting

A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Study to Assess the Safety, Pharmacokinetics, and Immunogenicity of HLX6018 in Healthy Subjects

IPF

China
Lindenwood University

Recruiting

Exercise-Induced Rates of Fat Oxidation With and Without Ingestion of a Caffeine-Based Energy Drink (EDX)

Cognition | Reaction Time | Exercise Performance | Energy Expenditure | Substrate Oxidation

United States
University of Chicago
Juvenile Diabetes Research Foundation; Cure Alliance

Recruiting

Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)

Diabetes Mellitus

United States
Guangzhou FineImmune Biotechnology Co., LTD.

Recruiting

Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors (TAL-T)

Advanced Solid Tumor | Immunotherapy | Tumor Associated Lymph Node T Cell

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO

Plaque Psoriasis Patients
Regeneron Pharmaceuticals

Not yet recruiting

A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC) (ROXI-CATH)

Venous Thromboembolism
argenx

Recruiting

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis (ADAPT SERON)

Generalized Myasthenia Gravis

United States
University Medical Center Groningen
GlaxoSmithKline

Recruiting

eGPA and Local Inflammation Within the Ear, Nose and Throat Area

EGPA - Eosinophilic Granulomatosis With Polyangiitis

Netherlands
Inhibrx, Inc.

Recruiting

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States

Search clinical trials for: Anti-TIGIT antibody

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations